Edina, MN

VitreoRetinal Surgery

Macular Degeneration

Geographic Atrophy

Atrophy

Macular Edema

Edema

Pathologic Neovascularization

Wet Macular Degeneration

Choroidal Neovascularization

Ranibizumab

Lampalizumab

ranibizumab

bevacizumab

Roche

Genentech

AbbVie

University of Pennsylvania

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD)

Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration

VitreoRetinal Surgery | Edina, MN

Site insights

Work at this site?

Active trials

Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration (BURGUNDY)

Trial sponsors